Seqens Seqens

X
[{"orgOrder":0,"company":"Vella Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vella Bioscience Inc. Granted First Patent For Use of Cannabinoids in Treating Antidepressant-Induced Female Sexual Dysfunction","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by Vella Bioscience

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Cannabinoids is a selective serotonin reuptake inhibitor (SSRI) which is being developed for treating antidepressant-induced female sexual dysfunction.

            Lead Product(s): Cannabidiol

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 29, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY